# Project State Continuation

Created: 2026-06-04  
Updated: 2026-06-08

Repository: `fyz1500wr/pharma-regulatory-clinical-intelligence-mcp`

This file is a compact continuation handoff for starting a new chat.

Canonical detailed status is in `.ai/PROJECT_STATE.md`. This file is the preferred short handoff when chat context becomes slow or too long.

## Current checkpoint

- Stable branch: `main`
- Latest confirmed merged PR: PR #104
- PR #104 merge commit: `bdabd104a86e4f0e32f13fe1013940bd6ed2363f`
- Latest completed workstream: CMC submission readiness mapping workflow, after clean-source digest dry-run completion
- Latest validation status: `PASS`
- Latest validation evidence:
  - `python -m pytest tests/test_readme_documentation_index.py -q` → `7 passed`
  - `python -m pytest -q` → `209 passed`
- Current tagged release: remains `v0.2.15-fda-abuse-detection-source-failure-diagnostics`; no new release tag was created for PR #97–#104 docs/product workflow work
- Open PRs at this checkpoint: none known after PR #104 merge
- Execution environment note: Codespaces quota is near limit until July 2026. For upcoming code/test work, default to Claude Code Web and Codex Web workflows. Do not assume Codespaces is available unless the user explicitly says it is available again.

## Current project phase

The project is still MVP v1 and must remain source- and scope-controlled.

Approved MVP source scope remains:

```text
FDA
TFDA
ClinicalTrials.gov
```

Do not add EMA, PMDA, NMPA, CTIS, WHO ICTRP, literature, patent, finance, news, company-alias database, corporate-family mapping, product ownership inference, dashboard, scheduler, alerting, persistence, HTTP/SSE transport, `.mcp.json`, GitHub automation, or other integrations unless explicitly approved.

The repository is not a GMP, QA, EDMS, eCTD publishing, official submission, clinical decision support, legal decision, medical decision, commercial intelligence, or management decision system. Do not store confidential, signed, GMP raw, QA-approved, official submission, or non-public company records in this repo.

## Recent PR sequence after PR #94

### PR #95

Updated project continuation/state after PR #94 digest source-coverage wording work.

Purpose:

- Preserve the PR #94 source-limitation re-test result.
- Record that digest output now distinguishes requested-source query errors from global source-health warnings.

### PR #96

Updated `.ai/PROJECT_STATE.md` after the post-PR #95 usability hardening checkpoint.

Purpose:

- Keep project-state handoff aligned with the source-limitation and usability-hardening phase.
- Confirm that future work should pause for direction calibration before adding new product features.

### PR #97 — Regulatory-clinical digest report workflow

Added:

```text
docs/regulatory_clinical_digest_report_workflow.md
```

Purpose:

- Define how MVP tool outputs should be turned into a PM/RA-facing regulatory-clinical intelligence memo.
- Require source coverage status, regulatory findings, clinical trial findings, company/sponsor association review, risks/caveats, PM/RA follow-up actions, human review checklist, and raw MCP traceability.
- Preserve the rule that unavailable sources are not zero-result sources.

### PR #98 — Digest example memo and prompt pack

Added:

```text
docs/regulatory_clinical_digest_example_memo.md
docs/regulatory_clinical_digest_prompt_pack.md
```

Purpose:

- Provide a controlled example PM/RA digest memo.
- Provide copy-paste prompts for turning MVP tool outputs into controlled PM/RA memo drafts.
- Add prompts for clean requested-source scenarios, partial requested-source coverage, company/sponsor association review, executive summary only, human review checklist, red flag review, and minimal one-page memo.

### PR #99 — Digest memo validation exercise

Added:

```text
docs/regulatory_clinical_digest_memo_validation_exercise.md
```

Purpose:

- Define a dry-run validation exercise before designing any runtime generator.
- Validate whether generated memos are readable, source-aware, and safe for PM/RA review.
- Require explicit query scope, source coverage interpretation, regulatory finding validation, clinical trial finding validation, company/sponsor association validation, risk/caveat validation, PM/RA follow-up validation, and red-flag sentence review.

### PR #100 — Continuation update after digest dry-run validation

Updated:

```text
PROJECT_STATE_CONTINUATION.md
```

Purpose:

- Record PR #97–#99 and the digest dry-run validation result.
- Preserve the `PASS_WITH_LIMITATIONS` dry-run finding.
- Recommend a report template contract before any runtime generator.

### PR #101 — Regulatory-clinical digest report template contract

Added:

```text
docs/regulatory_clinical_digest_report_template_contract.md
```

Purpose:

- Define a fixed docs/spec-only contract for controlled digest memo templates.
- Define required input object, required tool output inputs, required output object, source coverage labels, fixed memo sections, company/sponsor association fields, human review checklist, raw MCP traceability, and acceptance criteria before runtime implementation.
- Preserve explicit non-goals: no runtime report generator, template renderer, MCP-side report helper, new source, scheduler, dashboard, alerts, persistence, HTTP/SSE transport, `.mcp.json`, company alias database, corporate-family mapping, product ownership inference, or literature/patent/finance/news integration.

Validation:

```text
python -m pytest tests/test_readme_documentation_index.py -q
6 passed in 0.03s

python -m pytest -q
208 passed in 12.82s
```

### PR #102 — State update after digest template contract

Updated:

```text
.ai/PROJECT_STATE.md
PROJECT_STATE_CONTINUATION.md
```

Purpose:

- Record the PR #97–#101 digest/report docs-spec workstream.
- Record Codespaces quota limitation through July 2026.
- Preserve the recommendation to pause for direction calibration before runtime generator work.

### PR #103 — Clean-source digest dry-run memo

Added:

```text
docs/regulatory_clinical_digest_clean_source_dry_run.md
```

Purpose:

- Validate the digest report template contract under a clean requested-source scenario using TFDA and ClinicalTrials.gov.
- Explicitly exclude FDA from the clean-source exercise so FDA unavailable-source behavior is not confused with zero-result behavior.
- Preserve company/sponsor association caveats and working-intelligence labeling.

Validation:

```text
python -m pytest tests/test_readme_documentation_index.py -q
6 passed in 0.03s

python -m pytest -q
208 passed in 10.90s
```

Important caveat: the reported validation ran in a `work` checkout rather than a branch-name-confirmed `add-clean-source-digest-dry-run` checkout, but the working tree had no uncommitted changes.

### PR #104 — CMC submission readiness mapping workflow

Added:

```text
docs/cmc_submission_readiness_mapping_workflow.md
```

Purpose:

- Define a docs/spec-only workflow for mapping CMC project work into submission-readiness planning.
- Cover Module 3 gap mapping, vendor dependencies, method/stability dependencies, critical path rules, PM follow-up actions, and human review checklist.
- Preserve that the repository is not an official IND/eCTD submission system, eCTD publisher, GMP/QA record system, or EDMS.

Validation:

```text
python -m pytest tests/test_readme_documentation_index.py -q
7 passed

python -m pytest -q
209 passed
```

## Current overall product status

Estimated progress against the user's broader target system:

```text
Overall CMC PM + regulatory-clinical intelligence system: about 55% complete.
MVP regulatory-clinical intelligence prototype: about 70% complete.
```

What is now working:

- MVP source scope and guardrails are defined.
- FDA / TFDA / ClinicalTrials.gov MVP tools and safety interpretation rules exist.
- Source failure and source limitation wording is controlled.
- Regulatory-clinical digest memo workflow, prompt pack, validation exercise, template contract, and clean-source dry-run now exist.
- CMC submission readiness mapping workflow now exists as docs/spec-only.
- README documentation index tests continue to pass.

What remains intentionally not implemented:

- Runtime report generator.
- Template renderer.
- MCP-side report generation helper.
- Persistent source-failure event store.
- Dashboard, scheduler, alerting, external integration, or GitHub automation.
- Additional source expansion.
- Official eCTD publishing, EDMS, GMP/QA record, or submission record storage.

## Current guardrails

- Keep MVP source scope limited to FDA, TFDA, and ClinicalTrials.gov.
- Do not add new agencies, sources, MCP tools, transport modes, dashboards, schedulers, alerts, persistence, external integrations, GitHub automation, or repository automation unless explicitly approved.
- Keep future work small and phase-controlled.
- Use Traditional Chinese for user-facing discussion.
- Avoid accidental Japanese output.
- After repeated related PRs, pause for direction calibration before continuing.
- Repo is not a GMP, QA, EDMS, eCTD publishing, or official system of record.
- Do not store confidential, signed, GMP raw, QA-approved, or official submission records in this repo.
- Due to Codespaces quota limits until July 2026, prefer Claude Code Web and Codex Web for upcoming code/test work. Provide Codespaces commands only as optional fallback or when the user confirms availability.

## Recommended next step

Do not immediately build runtime automation.

Recommended next action:

```text
Create a non-confidential CMC mock inventory and Module 3 gap matrix dry-run.
```

Recommended document:

```text
docs/cmc_submission_readiness_mock_inventory.md
```

Purpose:

- Use fake/non-confidential sample CMC tasks to validate the PR #104 readiness workflow.
- Test whether the workflow can produce a PM-usable Module 3 gap matrix, vendor follow-up list, method/stability dependency map, and critical path summary.
- Keep it documentation-only and avoid storing confidential/GMP/QA/submission records.

Suggested mock items:

- DP potency assay qualification pending.
- DP stability report pending.
- DS specification needs CMC/RA review.
- Reference standard qualification status unknown.
- Vendor COA delayed.
- Excipient change rationale decision pending.

## New-chat opening prompt

請根據 GitHub repo `fyz1500wr/pharma-regulatory-clinical-intelligence-mcp`、`.ai/PROJECT_STATE.md`、以及 `PROJECT_STATE_CONTINUATION.md` 繼續。

請用繁體中文回覆，不要輸出日文。

請先確認：

1. `main` 是否已包含 PR #104；
2. `PROJECT_STATE_CONTINUATION.md` 和 `.ai/PROJECT_STATE.md` 是否已記錄 PR #103、PR #104、CMC readiness workflow、以及 209 passed validation；
3. 是否有 open PR；
4. 最新測試狀態；
5. 後續 code/test 工作是否應優先使用 Claude Code Web / Codex Web，而不是 Codespaces。

目前建議下一步是：

```text
Create a non-confidential CMC mock inventory and Module 3 gap matrix dry-run.
```

請維持 docs/spec-only，不要新增 runtime generator、MCP tool、source、scheduler、dashboard、alerts、persistence、HTTP/SSE、`.mcp.json`、company alias database、corporate-family mapping、product ownership inference、literature/patent/finance/news integration，除非我明確批准。
